Last edition
News about "bortezomib "
J&J's Tecvayli Cuts Death Risk in Phase III Multiple Myeloma Study
Phase III MajesTEC-9 shows Tecvayli significantly improves survival, reducing progression or death risk by 71 percent versus standard care in relapsed multiple myeloma.
Bortezomib | 15/01/2026 | By News Bureau | 121
Antengene Gets Malaysian Regulatory Agency Approval for XPOVIO Commercialization
Antengene has announced that Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO (selinexor).
Bortezomib | 06/08/2024 | By Aishwarya | 599
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy